Citius Pharmaceuticals CTXR Cash Flow Statement (2010-2026)

NASDAQ CTXR
$0.59 +0.00 (+0.64%)
As of: Sep 10, 2026 · 9:54 AM EDT
Reported Financials

Citius Pharmaceuticals Quarterly Cash Flow Statement

Periods 63 quarters
Latest Jun 2026

Citius Pharmaceuticals reported cash from operations of -$8.69M and free cash flow of -$8.69M for the quarter ended Jun 2026, down 60.8% year over year. This cash flow statement covers 63 quarters of results from Dec 2010 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-5.13M-9.23M-7.56M-8.86M-7.41M-3.59M-10.53M-8.48M-9.94M-9.23M-8.54M-10.57M-11.08M-10.28M-11.51M-9.20M-8.74M-9.39M-28.11M-11.92M
Share-based Compensation
0.46M0.90M9.32M9.40M0.98M13.25M13.43M13.38M3.08M17.39M17.12M9.19M2.64M2.52M5.14M5.55M2.89M11.32M3.79M11.32M
Deferred Taxes
0.14M0.14M0.14M0.14M0.14M0.14M0.14M0.14M0.26M0.26M0.26M0.26M0.26M-0.23M-0.11M
Change in Interest Receivables
-0.33M1.44M-0.48M-0.48M-0.34M1.08M-0.58M-0.55M
Cash from Operations
-5.59M-4.65M-9.67M-7.71M-6.33M-4.82M-7.85M-9.58M-6.80M-6.14M-7.79M-8.37M-5.91M-4.73M-4.54M-5.41M-11.88M-13.01M-1.30M-8.69M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.04M0.04M0.04M0.04M0.05M0.05M0.05M0.05M0.05M0.05M0.05M0.05M0.05M0.05M0.06M0.04M0.06M
Amortization of Deferred Charges
0.18M
Change in Working Capital
Change in Inventory
6.11M0.96M1.87M3.71M0.35M0.02M-0.03M
Change in Account Payables
-0.08M0.51M-0.08M-0.01M-0.53M0.37M1.19M0.35M-0.15M-0.28M0.02M-1.01M3.26M2.44M2.00M0.73M3.60M-2.67M-1.57M-1.42M
Change in Accured Expenses
0.26M2.51M-1.80M-0.04M0.10M-0.71M1.56M-1.36M-0.42M0.27M-1.31M0.58M-0.00M6.23M2.54M-0.26M-4.33M0.50M19.44M0.01M
Other Working Capital Changes
-0.04M-0.04M-0.04M-0.04M-0.05M-0.05M-0.05M-0.05M-0.05M-0.05M-0.05M-0.05M-0.06M-0.06M-0.06M-0.05M-0.07M0.02M-0.02M-0.04M
Investing Activities
Capital Expenditures
39.99M
Cash from Investing Activities
-40.00M-4.40M-0.60M-2.00M
Financing Activities
Other financing activities
13.77M-687.000.08M2.57M3.47M9.56M
Debt Issuance and Repayment
Long-Term Debt Issuances
Short-Term Debt issuances
Change in Capital Stock
Net Shares Issued and Repurchased
3.27M3.65M3.85M4.15M4.08M0.17M0.18M5.75M0.00M
Net Equity Issued and Repurchased
0.08M2.57M3.47M10.47M15.79M20.88M-0.06M4.45M
Misc.
Cash from Financing Activities
13.80M-687.00-3.75M2.57M3.47M11.47M15.79M20.88M-1.23M23.09M
Change in Cash
-45.59M-4.65M-9.67M-7.71M-6.33M-4.82M-7.82M4.22M-6.80M-6.14M-7.79M5.35M-14.66M-2.15M-1.07M6.06M-1.84M3.47M-3.13M12.42M
Free Cash Flow
-45.58M-4.65M-9.67M-7.71M-6.33M-4.82M-7.85M-9.58M-6.80M-6.14M-7.79M-8.37M-5.91M-4.73M-4.54M-5.41M-11.88M-13.01M-1.30M-8.69M
Net Cash Flow
-45.59M-4.65M-9.67M-7.71M-6.33M-4.82M-7.85M4.22M-6.80M-6.14M-7.79M-8.37M-9.66M-2.15M-1.07M6.06M3.91M3.47M-3.13M12.40M